Changes

| rowspan="11" |'''Level 1'''

| rowspan="11" |'''Level 1'''

well established evidence in NCCN guideline, WHO criteria, FDA-approved, COG recommendation, or based on large body of publications.

well established evidence in NCCN guideline,  

 

WHO criteria, FDA-approved, COG  

 

recommendation, or based on large body of publications.

|Hyperdiploidy (+3, +5, +7, +9, +11, +15, +21)

|Hyperdiploidy (+3, +5, +7, +9, +11, +15, +21)

|Good prognosis

|Good prognosis

|

|

|}

|}

'''Table 2 - Recurrent Abnormalities of copy number aberration (CNAs) and copy-neutral loss-of-heterozygosity (cnLOH) in plasma cell myeloma (Literature Review)'''. Summary table reviewing 65 papers applying FISH, CMA, NGS, and gene expression profiling for PCN diagnosis and prognosis. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics.

 

 

'''Table 2 - Recurrent Abnormalities of copy number aberration (CNAs) and copy-neutral loss-of-heterozygosity (cnLOH) in plasma cell myeloma (Literature Review)'''. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics.

{| class="wikitable"

{| class="wikitable"

|'''Chromosome'''

|'''Chromosome'''